Sign In
Buy VOR
$13.44
-0.220 (-1.61%)
At Close: Jun 03, 2026
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Oct 2025
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025
07:00am, Monday, 29'th Sep 2025
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
11:48am, Thursday, 25'th Sep 2025
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets
Vor Bio Appoints Navid Z. Khan, Ph.D.
08:00am, Tuesday, 23'rd Sep 2025
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the a
YANTAI, China , Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
04:15pm, Wednesday, 17'th Sep 2025
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clini
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
04:15pm, Friday, 12'th Sep 2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will parti
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
08:00am, Tuesday, 02'nd Sep 2025
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 26'th Aug 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will partic
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:35pm, Monday, 18'th Aug 2025
CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between Augus
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
11:15am, Wednesday, 13'th Aug 2025
Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 cl
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
08:30am, Monday, 04'th Aug 2025
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
08:30am, Monday, 21'st Jul 2025
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 18'th Jul 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as
